Gilead’s Remdesivir Significantly Reduces Risk of Hospitalization in High-Risk COVID-19 Patients, Finds Study
Gilead Sciences (Foster City, CA, USA; www.gilead.com) has announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. More...05 Oct 2021
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Rapid Sepsis Test
SeptiCyte RAPID
